Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
Xencor total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Xencor's total debt was $104.90M at Jun 30, 2026. For fiscal 2025 it was $119.75M, down 26.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.75M | -26.8% |
| FY2024 | Dec 31, 2024 | $163.61M | -13.7% |
| FY2023 | Dec 31, 2023 | $189.48M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $104.90M | -27.7% |
| Q1 FY2026 | Mar 31, 2026 | $108.53M | -29.7% |
| Q4 FY2025 | Dec 31, 2025 | $119.75M | -26.8% |
| Q3 FY2025 | Sep 30, 2025 | $133.14M | -23.0% |
| Q2 FY2025 | Jun 30, 2025 | $145.02M | -19.3% |
| Q1 FY2025 | Mar 31, 2025 | $154.38M | -16.6% |
| Q4 FY2024 | Dec 31, 2024 | $163.61M | -13.7% |
| Q3 FY2024 | Sep 30, 2024 | $172.80M | – |
| Q2 FY2024 | Jun 30, 2024 | $179.76M | – |
| Q1 FY2024 | Mar 31, 2024 | $185.10M | – |
| Q4 FY2023 | Dec 31, 2023 | $189.48M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
See a number that looks wrong?